New Study To Measure Impact of Supplemental Oxygen in Pulmonary Fibrosis

New Study To Measure Impact of Supplemental Oxygen in Pulmonary Fibrosis

A novel study on the impact of supplemental oxygen prescription in pulmonary fibrosis entitled “Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis” was published in the journal BMC Pulmonary Medicine by Amanda Belkin, part of Dr. Jeffrey J Swigris’group from Autoimmune Lung Center and Interstitial Lung…

Promising Experimental IPF Drug Receives Orphan Status

MediciNova, Inc.’s idiopathic pulmonary fibrosis (IPF) drug candidate MN-001 (tipelukast) was recently granted orphan drug status by the US Food and Drug Administration. As a result, MediciNova will have exclusive rights to market MN-001 to treat patients with IPF, should it be approved following clinical trials. “We are very pleased…

ProMetic Will Explore PB-4050 Potential as Idiopathic PF Treatment

ProMetic Life Sciences has just announced that it will begin research on the application of their lead pipeline product for pulmonary fibrosis, PBI-4050, in idiopathic pulmonary fibrosis (IPF), an unusual type of PF that leads to spontaneous lung scarring and is estimated to affect over 130,000 Americans. Every…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums